Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial

Abstract Background We aimed to evaluate the efficacy and safety of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) plus TPC chemotherapy (NAB-paclitaxel, cisplatin or lobaplatin, and capecitabine) in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) who failed to PD-1 i...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yaofei Jiang, Weixin Bei, Lin Wang, Nian Lu, Cheng Xu, Hu Liang, Liangru Ke, Yanfang Ye, Shuiqing He, Shuhui Dong, Qin Liu, Chuanrun Zhang, Xuguang Wang, Weixiong Xia, Chong Zhao, Ying Huang, Yanqun Xiang, Guoying Liu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-03-01
coleção:	BMC Medicine
Assuntos:	Cadonilimab PD-1/CTLA-4 bispecific Nasopharyngeal carcinoma Immunotherapy rechallenge
Acesso em linha:	https://doi.org/10.1186/s12916-025-03985-4
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!